scholarly journals ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis

Cell Reports ◽  
2021 ◽  
Vol 36 (8) ◽  
pp. 109602
Author(s):  
Yuan Qian ◽  
Gabriel Arellano ◽  
Igal Ifergan ◽  
Jean Lin ◽  
Caroline Snowden ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cell Differentiation ◽  
Th17 Cell ◽  
Th17 Cell Differentiation

scholarly journals Regulation of Suppressors of Cytokine Signaling as a Therapeutic Approach in Autoimmune Diseases, with an Emphasis on Multiple Sclerosis

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Vinod S. Ramgolam ◽  
Silva Markovic-Plese
Keyword(s):  
Multiple Sclerosis ◽  
Cell Differentiation ◽  
Autoimmune Diseases ◽  
Th17 Cell ◽  
Inflammatory Cells ◽  
Cytokine Signaling ◽  
Rapid Induction ◽  
Th17 Cell Differentiation ◽  
Socs3 Expression ◽  
Attractive Therapeutic Target

Multiple sclerosis (MS) is an inflammatory demyelinating, presumably autoimmune disease of the central nervous system (CNS). Among the available MS therapies, interferon (IFN)β and the recently introduced statins have been reported to exert their immunomodulatory effects through the induction of SOCS1 and SOCS3 in various inflammatory cell subsets. The SOCS proteins negatively regulate cytokine and Toll-like receptors- (TLR-) induced signaling in the inflammatory cells. SOCS1 and SOCS3 have been reported to play an important role in the regulation of Th17-cell differentiation through their effects on the cells of the innate and adaptive immune systems. IFNβ and statins inhibit Th17-cell differentiation directly and indirectly via induction of SOCS1 and SOCS3 expression in monocytes, dendritic cells (DCs), and B-cells. Due to their rapid induction and degradation, and SOCS-mediated regulation of multiple cytokine-signaling pathways, they represent an attractive therapeutic target in the autoimmune diseases, and particularly relapsing remitting (RR) MS.

Sign in / Sign up

Export Citation Format

Share Document